The PPAR-γ agonist 15-deoxy- Δ 12, 14-prostaglandin J 2 attenuates microglial production of IL-12 family cytokines: Potential relevance to Alzheimer's disease

PPAR Research

Volumn , Issue , 2008, Pages

  Xu, Jihong ^a   Barger, Steven W ^b   Drew, Paul D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; MYELOID DIFFERENTIATION FACTOR 88; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TH1 CELL;

EID: 47349118631     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/349185     Document Type: Article

References (55)

1. Abbas N., Bednar I., Mix E., Up-regulation of the inflammatory cytokines IFN- γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice Journal of Neuroimmunology 2002 126 1-2 50 57
2. Schenk D., Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning Nature Reviews Neuroscience 2002 3 10 824 828
3. Weiner H. L., Frenkel D., Immunology and immunotherapy of Alzheimer's disease Nature Reviews Immunology 2006 6 5 404 416
4. Games D., Buttini M., Kobayashi D., Schenk D., Seubert P., Mice as models: transgenic approaches and Alzheimer's disease Journal of Alzheimer's Disease 2006 9 supplement 3 133 149
5. Morgan D., Immunotherapy for Alzheimer's disease Journal of Alzheimer's Disease 2006 9 supplement 3 425 432
6. Janus C., Pearson J., McLaurin J., A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 2000 408 6815 979 982
7. Schenk D., Barbour R., Dunn W., Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 1999 400 6740 173 177
8. Wilcock D. M., Gordon M. N., Ugen K. E., Number of A β inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels DNA and Cell Biology 2001 20 11 731 736
9. Mohajeri M. H., Saini K., Schultz J. G., Wollmer M. A., Hock C., Nitsch R. M., Passive immunization against β -amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation Journal of Biological Chemistry 2002 277 36 33012 33017
10. Wilcock D. M., Rojiani A., Rosenthal A., Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition Journal of Neuroscience 2004 24 27 6144 6151
11. Orgogozo J.-M., Gilman S., Dartigues J.-F., Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization Neurology 2003 61 1 46 54
12. Monsonego A., Imitola J., Petrovic S., A β -induced meningoencephalitis is IFN- γ -dependent and is associated with T cell-dependent clearance of A β in a mouse model of Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2006 103 13 5048 5053
13. Heneka M. T., O'Banion M. K., Inflammatory processes in Alzheimer's disease Journal of Neuroimmunology 2007 184 1-2 69 91
14. Breitner J. C. S., The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease Annual Review of Medicine 1996 47 401 411
15. Meda L., Cassatella M. A., Szendrei G. I., Activation of microglial cells by β -amyloid protein and interferon- γ Nature 1995 374 6523 647 650
16. Saura C. A., Chen G., Malkani S., Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice Journal of Neuroscience 2005 25 29 6755 6764
17. Oppmann B., Lesley R., Blom B., Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 2000 13 5 715 725
18. Langrish C. L., McKenzie B. S., Wilson N. J., de Waal Malefyt R., Kastelein R. A., Cua D. J., IL-12 and IL-23: master regulators of innate and adaptive immunity Immunological Reviews 2004 202 96 105
19. Becher B., Durell B. G., Noelle R. J., Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12 Journal of Clinical Investigation 2002 110 4 493 497
20. Cua D. J., Sherlock J., Chen Y., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 2003 421 6924 744 748
21. Gran B., Zhang G.-X., Yu S., IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination Journal of Immunology 2002 169 12 7104 7110
22. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocrine Reviews 1999 20 5 649 688
23. Gasparini L., Ongini E., Wenk G., Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action Journal of Neurochemistry 2004 91 3 521 536
24. Heneka M. T., Sastre M., Dumitrescu-Ozimek L., Acute treatment with the PPAR γ agonist pioglitazone and ibuprofen reduces glial inflammation and A β 1-42 levels in APPV717I transgenic mice Brain 2005 128 6 1442 1453
25. Takeda K., Kaisho T., Akira S., Toll-like receptors Annual Review of Immunology 2003 21 335 376
26. Harii N., Lewis C. J., Vasko V., Thyrocytes express a functional Toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis Molecular Endocrinology 2005 19 5 1231 1250
27. Kielian T., Toll-like receptors in central nervous system glial inflammation and homeostasis Journal of Neuroscience Research 2006 83 5 711 730
28. Balistreri C. R., Candore G., Listì F., Role of TLR4 polymorphisms in inflammatory responses: implications for unsuccessful aging Annals of the New York Academy of Sciences 2007 1119 1 203 207
29. Walter S., Letiembre M., Liu Y., Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease Cellular Physiology and Biochemistry 2007 20 6 947 956
30. Tahara K., Kim H.-D., Jin J.-J., Maxwell J. A., Li L., Fukuchi K., Role of toll-like receptor signalling in A β uptake and clearance Brain 2006 129 11 3006 3019
31. McCarthy K. D., de Vellis J., Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue Journal of Cell Biology 1980 85 3 890 902
32. Drew P. D., Chavis J. A., The cyclopentone prostaglandin 15-deoxy- Δ12,14 prostaglandin J2 represses nitric oxide, TNF- α, and IL-12 production by microglial cells Journal of Neuroimmunology 2001 115 1-2 28 35
33. Mrak R. E., Griffin W. S. T., Common inflammatory mechanisms in Lewy body disease and Alzheimer disease Journal of Neuropathology & Experimental Neurology 2007 66 8 683 686
34. Xu J., Drew P. D., Peroxisome proliferator-activated receptor- γ agonists suppress the production of IL-12 family cytokines by activated glia Journal of Immunology 2007 178 3 1904 1913
35. Maier M., Seabrook T. J., Lazo N. D., Short amyloid- β (A β) immunogens reduce cerebral A β load and learning deficits in an Alzheimer's disease mouse model in the absence of an A β -specific cellular immune response Journal of Neuroscience 2006 26 18 4717 4728
36. Morgan D., Diamond D. M., Gottschall P. E., A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 2000 408 6815 982 985. Erratum in Nature, vol. 412, no. 6847, p. 660, 2001
37. Bard F., Cannon C., Barbour R., Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nature Medicine 2000 6 8 916 919
38. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J.-C., Paul S. M., Holtzman D. M., Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2001 98 15 8850 8855
39. Bayer A. J., Bullock R., Jones R. W., Evaluation of the safety and immunogenicity of synthetic A β 42 (AN1792) in patients with AD Neurology 2005 64 1 94 101
40. Gilman S., Koller M., Black R. S., Clinical effects of A β immunization (AN1792) in patients with AD in an interrupted trial Neurology 2005 64 9 1553 1562
41. Nicolll J. A. R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R. O., Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: a case report Nature Medicine 2003 9 4 448 452
42. Ferrer I., Boada Rovira M., Sánchez Guerra M. L., Rey M. J., Costa-Jussá F., Neuropathology and pathogenesis of encephalitis following amyloid- β immunization in Alzheimer's disease Brain Pathology 2004 14 1 11 20
43. Masliah E., Hansen L., Adame A., A β vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease Neurology 2005 64 1 129 131
44. Weiner H. L., Selkoe D. J., Inflammation and therapeutic vaccination in CNS diseases Nature 2002 420 6917 879 884
45. Monsonego A., Weiner H. L., Immunotherapeutic approaches to Alzheimer's disease Science 2003 302 5646 834 838
46. Monsonego A., Zota V., Karni A., Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease Journal of Clinical Investigation 2003 112 3 415 422
47. Kielian T., Drew P. D., Effects of peroxisome proliferator-activated receptor- γ agonists on central nervous system inflammation Journal of Neuroscience Research 2003 71 3 315 325
48. Heneka M. T., Landreth G. E., Feinstein D. L., Role of peroxisome proliferator-activated receptor- γ in Alzheimer's disease Annals of Neurology 2001 49 2 276
49. Yan Q., Zhang J., Liu H., Anti-inflammatory drug therapy alters β -amyloid processing and deposition in an animal model of Alzheimer's disease Journal of Neuroscience 2003 23 20 7504 7509
50. Pedersen W. A., McMillan P. J., Kulstad J. J., Leverenz J. B., Craft S., Haynatzki G. R., Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice Experimental Neurology 2006 199 2 265 273
51. Sastre M., Dewachter I., Landreth G. E., Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor- γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β -secretase Journal of Neuroscience 2003 23 30 9796 9804
52. Watson G. S., Cholerton B. A., Reger M. A., Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study American Journal of Geriatric Psychiatry 2005 13 11 950 958
53. Risner M. E., Saunders A. M., Altman J. F. B., Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease The Pharmacogenomics Journal 2006 6 4 246 254
54. Fassbender K., Walter S., Kühl S., The LPS receptor (CD14) links innate immunity with Alzheimer's disease The FASEB Journal 2004 18 1 203 205
55. Liu Y., Walter S., Stagi M., LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide Brain 2005 128 8 1778 1789